The definition of value by patients with cancer does not necessarily coincide with other definitions by other stakeholders.
Enzalutamide (Xtandi) outperformed bicalutamide (Casodex) in separate phase 2 clinical trials of men with prostate cancer, according to data presented at the 2015 American Urological Association annual meeting.
Clinicians will soon have more targeted therapies at their disposal, including drugs with novel mechanisms of action.
TMed will improve the selection of treatments by adding back and analyzing all the relevant data about the variability of response and the multiplicity of causes…from thousands, if not millions, of patients.
I believe that the dialogue and thoughts being shared and expressed by all cancer care stakeholders is exactly what we need today. Frankly, the conversation has been underground far too long, but the headlines today have been focused solely on the drug cost. Anyone thinking that cancer care costs are going to go down, simply doesn’t understand healthcare economics, because the cost to society will continue to go up over time, with true innovation and value delivered.
  • FDA Approved Gefitinib with a Companion Diagnostic Test for First-Line Treatment of Patients with Metastatic Lung Cancer and EGFR Mutations
  • Sonidegib Approved for Locally Advanced Basal-Cell Carcinoma
  • Brentuximab Vedotin Receives New Indication for Patients with Hodgkin Lymphoma
  • Rolapitant a New Antiemetic Agent Approved for CINV Prevention
  • Medicare to Cover More of the Cost of Blincyto, Citing Substantial Benefits
  • FDA Grants Priority Review for 2 Investigational Cancer Drugs
  • Current System Favors Development of Drugs for Late-Stage Cancer
Boston, MA—Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer (NEPC), an aggressive and rapidly progressing entity that is increasingly being recognized in patients with advanced disease and signals poor overall survival. The signature, derived from genomic, transcription, and methylation analysis, relies heavily on epigenetic alterations.
Boston, MA—Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
San Diego, CA—The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompt­­ed Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. The results of this study were presented at the 2015 Academy of Managed Care Pharmacy annual meeting.
Page 1 of 2
Results 1 - 10 of 19
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology